---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004190"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:59:46.546765+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Spero reports preliminary cash of ~$109M as of Dec 31, 2022; updates investor presentation

## Summary
- Preliminary cash, cash equivalents and marketable securities of ~$109M as of Dec 31, 2022 (unaudited, subject to change).
- Updated investor presentation highlights SPR720 as a potential first-line oral therapy for NTM infections.
- Partnerships for tebipenem HBr and SPR206 are noted to support a strong balance sheet.
- Audited FY2022 financials are not yet available; preliminary estimate may differ materially.

## SEC filing metadata
- accession: 0001193125-23-004190
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312523004190/0001193125-23-004190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312523004190/d411727d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004190
- JSON: https://secwatch.observer/filing/0001193125-23-004190.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004190.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.